“From Inborn Errors of Metabolism to Oncology”
Personalized Medicine starts with Personalized Diagnostics for your optimal treatment and best clinical outcome.
We deliver vital health information for you.
ARCHIMEDlife is a highly-innovative diagnostic laboratory pioneering new ways to provide better and faster diagnostic services.
Personalized Diagnostics
From routine testing to clinical studies we are a laboratory service provider with strong focus on personalized diagnostics including rare disorders. Our promise is to provide high quality laboratory tests to identify any harmful disease at the earliest time for best clinical outcome.
“Our commitment: improving health through better, faster and earlier diagnosis giving the best chance for treatment and best clinical outcomes.”
NEWS
Diagnostics ・Research・Development
ISO 15189. We made it.
on 11 Sep, 2018
ARCHIMEDlife, a new global player for laboratory diagnostics for Rare Disorders and other niche diagnostic services, receives ISO 15189 accreditation. ARCHIMEDlife announces its accreditation for its Medical Laboratories in Clinical Chemistry and...
Read More
First LEA assay launched
on 14 Mrz, 2018
LEA2 MPS Panel Our first LEA2 (Lysosomal Enzyme Activity) assay has now been started and with it several mucopolysaccharidoses (MPS) can be diagnosed from one single Dried Blood Spot within a few...
Read More
Awarded work starting into a prospective study: Hemoglobinopathies and Thalassemias
on 14 Mrz, 2018
Our awarded work (Poster Finalist at MSACL Europe, also see the PDF Poster Hemoglobinopathies_MSACL) on hemoglobinopathies and thalassemias is now starting into a prospective study in cooperation with the University Medical Center Hamburg-Eppendorf,...
Read More
Novel diagnostics for Rare Disorders: Fabry in females, presented at WorldSymposium
on 07 Mrz, 2018
The parallel measurement of lyso-GL-3 (lyso-Gb3) for Fabry disease is of high importance particularly for potential female Fabry patients, otherwise women at risk might be missed and consequently be undiagnosed. We analyzed...
Read More
5 years ARCHIMEDlife – Thanks to our partners, clients and friends!
on 21 Nov, 2017
The 21st of November 2017 is ARCHIMEDlife´s 5th anniversary, a proof that out of an idea you can evolve a successful company with dedicated people and ongoing improvement. It is time to...
Read More
Become part of our readers´ community
on 12 Nov, 2017
You can easily subscribe to our bi-monthly ARCHIMEDlife Newsletter and read about laboratory diagnostics, research studies, scientific publications and rare diseases – first hand and for free! If you do not want...
Read More
We were there: Asia-Pacific Conference on Human Genetics
on 06 Nov, 2017
We took part in the 12th Asia-Pacific Conference on Human Genetics “Genomic Medicine and Clinical Practice” from 8th to 10th of November in Bangkok. Medical scientists, genetic experts and healthcare professionals from...
Read More
Pharmaboardroom.com: Interview with ARCHIMEDlife CEO David Kasper in Austria issue of “Healthcare and Life Sciences Review”
on 16 Okt, 2017
Pharmaboardroom.com interviewed ARCHIMEDlife CEO David Kasper for their latest Austria issue of „Healthcare and Life Sciences Review”. Find out why he founded ARCHIMEDlife in a privately-held setting and which needs ARCHIMEDlife satisfies...
Read More
In the press: „Rare Diseases depend on correct diagnosis“ – Interview with Assoc. Prof. DI DDr. Kasper in seltenekrankheit.at about Morbus Fabry
on 26 Sep, 2017
ARCHIMEDlife founder Assoc. Prof. DI DDr. David C. Kasper in an interview about the correct diagnosis of Morbus Fabry and the challenges for physicians in detecting this x-chromosomal inherited disease. (in GERMAN) A...
Read MoreARCHIMEDlife @ MSACL Salzburg: Mass Spectrometry Applications to Clinical Lab, 10.- 14.9.17
on 13 Sep, 2017
We are proud to be a regular part of MSACL – this year in Salzburg from 10.- 14. September 2017. Together with many other leading academic and industrial experts we explore and...
Read More
Our new Website is online!
on 01 Sep, 2017
WELCOME! We are happy to announce that our new website is online. From now on you can find all relevant information regarding laboratory diagnostics, rare disorders and diverse research activities here on...
Read More
Newborn Screening Awareness Month: Expanded Newborn Screening for dozens of metabolic diseases
on 01 Sep, 2017
September is Newborn Screening Awareness Month. Not only throughout this time we like to remind you, that you can easily test your baby for dozens of metabolic and genetic diseases with only...
Read MoreNow published: A consensus guideline for newborn screening by mass spectrometry
on 25 Jul, 2017
An updated Consensus Guideline by worldwide experts is now available: See the publication of CLSI document NBS04-Ed2, Newborn Screening by Tandem Mass Spectrometry. The document is now available by the Clinical & Laboratory...
Read More
Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease
on 05 Jul, 2017
Background: Fabry disease (FD) is a rare X-linked lysosomal storage disease caused by mutations in the α-galactosidase A (GLA) gene causing deficiency of α-galactosidase A which results in progressive glycosphingolipid accumulation, especially...
Read More
Detect Severe combined immunodeficiency (SCID) early at birth!
on 21 Jun, 2017
We offer TREC (T-cell receptor excision circle) DNA testing from Dried Blood Spots to aid in screening newborns for Severe Combined Immunodeficiency (SCID). SCID is a group of disorders characterized by a...
Read More
Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease
on 16 Jun, 2017
Background: Fabry disease (FD), an X-linked lysosomal storage disorder, results from the deficient activity of α-galactosidase A (α-Gal A) and the accumulation of its substrates, globotriaosylceramide (Gb3) and its deacylated derivative, globotriaosyl-sphingosine...
Read MoreMetabolic progression to clinical phenotype in classic Fabry disease
on 03 Jan, 2017
Background: Fabry disease is an X-linked lysosomal storage disorder due to α-galactosidase A (α-Gal A) deficiency. Clinical onset of Fabry disease is preceded by significant storage of globotriaosylceramide (Gb3) and related glycosphingolipids,...
Read More
Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes
on 19 Okt, 2016
Background: Fabry disease (FD) is a rare X-linked lysosomal storage disorder due to mutations in the a-galactosidase A gene (GLA) that result in absent or markedly reduce a-galactosidase A (a-GalA) enzymatic activity. As...
Read More
Upcoming expanded Testing for Lysosomal Storage Disorders
on 21 Sep, 2016
ARCHIMEDlife started offering genetic testing for Gaucher, Niemann-Pick A/B, MPS-I, Pompe and Fabry disease. More recently, we expanded our services for MPS II/ IVA and VI. Work is also underway to add...
Read More
Homocystein and Methylmalonic acid – Novel 2nd-tier tests
on 21 Sep, 2016
In the healthy cell metabolism homocysteine is a short-living intermediate product, which is either transformed or removed by various metabolic pathways. The malfunction of the methionine metabolism therefore causes an increase of...
Read More